Cargando…

Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression

Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Diniz, Breno S., Sibille, Etienne, Ding, Ying, Tseng, George, Aizenstein, Howard, Lotrich, Francis, Becker, James T., Lopez, Oscar L., Lotze, Michael T., Klunk, William E., Reynolds, Charles F., Butters, Meryl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494754/
https://www.ncbi.nlm.nih.gov/pubmed/25092249
http://dx.doi.org/10.1038/mp.2014.76
_version_ 1782380147503005696
author Diniz, Breno S.
Sibille, Etienne
Ding, Ying
Tseng, George
Aizenstein, Howard
Lotrich, Francis
Becker, James T.
Lopez, Oscar L.
Lotze, Michael T.
Klunk, William E.
Reynolds, Charles F.
Butters, Meryl A.
author_facet Diniz, Breno S.
Sibille, Etienne
Ding, Ying
Tseng, George
Aizenstein, Howard
Lotrich, Francis
Becker, James T.
Lopez, Oscar L.
Lotze, Michael T.
Klunk, William E.
Reynolds, Charles F.
Butters, Meryl A.
author_sort Diniz, Breno S.
collection PubMed
description Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflected in specific biomarkers. Our aim was to evaluate peripheral (blood-based) evidence for biological pathways associated with cognitive impairment in older adults with LLD. To this end, we used a data-driven comprehensive proteomic analysis (multiplex immunoassay including 242 proteins), along with measures of structural brain abnormalities (gray matter atrophy and white matter hyperintensity volume via MRI), and brain amyloid-β (Aβ) deposition (PiB-PET). We analyzed data from 80 older adults with remitted major depression (36 with Mild Cognitive Impairment (LLD+MCI) and 44 with normal cognitive function (LLD+NC)). LLD+MCI was associated with differential expression of 24 proteins (p <0.05 and q-value <0.30) related mainly to the regulation of immune-inflammatory activity, intracellular signaling, cell survival, and protein and lipid homeostasis. Individuals with LLD+MCI also showed greater white matter hyperintensity burden compared with LLD+NC (p=0.015). We observed no differences in gray matter volume or brain Aβ deposition between groups. Machine learning analysis showed that a group of three proteins (Apo AI, IL-12, and stem cell factor) yielded accuracy of 81.3%, sensitivity of 75%, and specificity of 86.4% in discriminating participants with MCI from those with normal cognitive function (with an averaged cross-validation accuracy of 76.3%, sensitivity of 69.4% and specificity of 81.8% with nested cross-validation considering the model selection bias). Cognitive impairment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immune-inflammatory control, cell survival, intracellular signaling, protein and lipid homeostasis, and clotting processes. These results suggest that individuals with LLD and cognitive impairment may be more vulnerable to accelerated brain aging and shed light on possible mediators of their elevated risk for progression to dementia.
format Online
Article
Text
id pubmed-4494754
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-44947542015-11-01 Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression Diniz, Breno S. Sibille, Etienne Ding, Ying Tseng, George Aizenstein, Howard Lotrich, Francis Becker, James T. Lopez, Oscar L. Lotze, Michael T. Klunk, William E. Reynolds, Charles F. Butters, Meryl A. Mol Psychiatry Article Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. The biological mechanisms underlying cognitive impairment in LLD are complex and likely involve abnormalities in multiple pathways, or “cascades,” reflected in specific biomarkers. Our aim was to evaluate peripheral (blood-based) evidence for biological pathways associated with cognitive impairment in older adults with LLD. To this end, we used a data-driven comprehensive proteomic analysis (multiplex immunoassay including 242 proteins), along with measures of structural brain abnormalities (gray matter atrophy and white matter hyperintensity volume via MRI), and brain amyloid-β (Aβ) deposition (PiB-PET). We analyzed data from 80 older adults with remitted major depression (36 with Mild Cognitive Impairment (LLD+MCI) and 44 with normal cognitive function (LLD+NC)). LLD+MCI was associated with differential expression of 24 proteins (p <0.05 and q-value <0.30) related mainly to the regulation of immune-inflammatory activity, intracellular signaling, cell survival, and protein and lipid homeostasis. Individuals with LLD+MCI also showed greater white matter hyperintensity burden compared with LLD+NC (p=0.015). We observed no differences in gray matter volume or brain Aβ deposition between groups. Machine learning analysis showed that a group of three proteins (Apo AI, IL-12, and stem cell factor) yielded accuracy of 81.3%, sensitivity of 75%, and specificity of 86.4% in discriminating participants with MCI from those with normal cognitive function (with an averaged cross-validation accuracy of 76.3%, sensitivity of 69.4% and specificity of 81.8% with nested cross-validation considering the model selection bias). Cognitive impairment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immune-inflammatory control, cell survival, intracellular signaling, protein and lipid homeostasis, and clotting processes. These results suggest that individuals with LLD and cognitive impairment may be more vulnerable to accelerated brain aging and shed light on possible mediators of their elevated risk for progression to dementia. 2014-08-05 2015-05 /pmc/articles/PMC4494754/ /pubmed/25092249 http://dx.doi.org/10.1038/mp.2014.76 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Diniz, Breno S.
Sibille, Etienne
Ding, Ying
Tseng, George
Aizenstein, Howard
Lotrich, Francis
Becker, James T.
Lopez, Oscar L.
Lotze, Michael T.
Klunk, William E.
Reynolds, Charles F.
Butters, Meryl A.
Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title_full Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title_fullStr Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title_full_unstemmed Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title_short Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression
title_sort plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494754/
https://www.ncbi.nlm.nih.gov/pubmed/25092249
http://dx.doi.org/10.1038/mp.2014.76
work_keys_str_mv AT dinizbrenos plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT sibilleetienne plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT dingying plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT tsenggeorge plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT aizensteinhoward plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT lotrichfrancis plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT beckerjamest plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT lopezoscarl plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT lotzemichaelt plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT klunkwilliame plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT reynoldscharlesf plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression
AT buttersmeryla plasmabiosignatureandbrainpathologyrelatedtopersistentcognitiveimpairmentinlatelifedepression